AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12656871 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Gide membrane (Group A)
Number of subjects: 21
Study 12656871 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss (Group B)
Number of subjects: 21
Study 12656871 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing (Group C)
Number of subjects: 21
Study 11191543 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human IL-12 (0.1, 0.25, 0.5 microg/kg)
Number of subjects: 39
Study 11191543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9663842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine effervescent tablets 150 mg
Number of subjects: 15
Study 9663842 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine effervescent tablets 300 mg
Number of subjects: 15
Study 9663842 — intervention group
Group type: COMPARATOR
Intervention: Famotidine fast-dissolving tablets 20 mg
Number of subjects: 15
Study 9663842 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole capsules 20 mg
Number of subjects: 15
Study 1553114 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon
Number of subjects: 27
Study 1553114 — intervention group
Group type: COMPARATOR
Intervention: Pancrease
Number of subjects: 27
Study 2952668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, 7.5 mg daily for one cycle in addition to Clomid and/or gonadotrophins
Number of subjects: 73
Study 2952668 — intervention group
Group type: COMPARATOR
Intervention: Non-prednisolone group (control)
Number of subjects: 73
Study 2952668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone group
Number of subjects: 73
Study 31378155 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to video news stories and print articles on child safety topics
Number of subjects: 1081
Study 29861224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile-kinesthetic stimulation (TKS) performed by mothers, 15 minutes, two times a day for at least 28 consecutive days.
Number of subjects: 60
Study 29861224 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 60
Study 27189295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/kg) for 5 minutes
Number of subjects: 74
Study 27189295 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil with an effect site concentration of 1.5 ng/mL until endotracheal extubation
Number of subjects: 74
Study 25213871 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A System
Number of subjects: 0
Study 25213871 — intervention group
Group type: COMPARATOR
Intervention: Best physician's choice (BPC) chemotherapy
Number of subjects: 0
Study 25213871 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A System with compliance ≥75%
Number of subjects: 0
Study 25213871 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A System with compliance <75%
Number of subjects: 0
Study 22700854 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 4591
Study 22700854 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 4591
Study 22700854 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4591
Study 22700854 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg (urgent surgery)
Number of subjects: 4591
Study 22700854 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg (urgent surgery)
Number of subjects: 4591
Study 22700854 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (urgent surgery)
Number of subjects: 4591
Study 20473184 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz arm
Number of subjects: 0
Study 20473184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir arm
Number of subjects: 0
Study 20473184 — intervention group
Group type: COMPARATOR
Intervention: Model prediction
Number of subjects: 0
Study 17619534 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM monotherapy (100 mg/day, PO, for 24 months)
Number of subjects: 45
Study 17619534 — intervention group
Group type: COMPARATOR
Intervention: LAM plus IFN-alpha combination therapy (IFN-alpha-2b, 10 MU, tiw, SC, for 6 months plus LAM 100 mg/day, PO, for 24 months)
Number of subjects: 45
Study 17140102 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene and cell therapy aimed at stimulating angiogenesis
Number of subjects: 0
Study 17140102 — intervention group
Group type: COMPARATOR
Intervention: Prostanoids, spinal cord stimulation, and lumbar sympathectomy
Number of subjects: 0
Study 15013271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 219
Study 15013271 — intervention group
Group type: COMPARATOR
Intervention: Non-users of oral contraceptives
Number of subjects: 219
Study 10746839 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 48
Study 10746839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8931610 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (n = 416)
Number of subjects: 837
Study 8931610 — intervention group
Group type: COMPARATOR
Intervention: No radiation therapy (n = 421)
Number of subjects: 837
Study 1347803 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 U r‐HuEPO
Number of subjects: 25
Study 1347803 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 U r‐HuEPO
Number of subjects: 25
Study 1347803 — intervention group
Group type: EXPERIMENTAL
Intervention: 9000 U r‐HuEPO
Number of subjects: 25
Study 1347803 — intervention group
Group type: COMPARATOR
Intervention: No r‐HuEPO (control)
Number of subjects: 25
Study 1347803 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (all doses)
Number of subjects: 25
Study 1347803 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO
Number of subjects: 25
Study 3887076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of lidocaine
Number of subjects: 20
Study 3887076 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 29525738 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 340
Study 29525738 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic disclaimer label
Number of subjects: 340
Study 29525738 — intervention group
Group type: EXPERIMENTAL
Intervention: Consequence label
Number of subjects: 340
Study 29525738 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational label
Number of subjects: 340
Study 29525738 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic label
Number of subjects: 340
Study 27775778 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented TPN
Number of subjects: 47
Study 27775778 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 47
Study 24462053 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Home Visits (PHV)
Number of subjects: 459
Study 24462053 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior Meetings
Number of subjects: 459
Study 24462053 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 459
Study 22504855 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator training (SIM)
Number of subjects: 61
Study 22504855 — intervention group
Group type: EXPERIMENTAL
Intervention: Crew resource management training (CRM)
Number of subjects: 61
Study 22504855 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 61
Study 20570360 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival lidocaine injection
Number of subjects: 65
Study 20570360 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 65
Study 20570360 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival lidocaine injection (crossover group)
Number of subjects: 65
Study 20570360 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (crossover group)
Number of subjects: 65
Study 20570360 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for treatment
Number of subjects: 65
Study 18505574 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity study participants (240/560)
Number of subjects: 560
Study 18505574 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (320/560)
Number of subjects: 560
Study 15647219 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12628632 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently dosed (n=21)
Number of subjects: 39
Study 12628632 — intervention group
Group type: COMPARATOR
Intervention: 24 hr abstinent (n=18)
Number of subjects: 39
Study 10593347 — intervention group
Group type: EXPERIMENTAL
Intervention: US 3 G: 1 g of stanol (ester form) per 8‐g serving of a US reformulation 3 times a day
Number of subjects: 318
Study 10593347 — intervention group
Group type: EXPERIMENTAL
Intervention: US 2 G: 0.67 g of stanol (ester form) per 8‐g serving of a US reformulation 3 times a day
Number of subjects: 318
Study 10593347 — intervention group
Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 318
Study 8915574 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of trkA receptors in astrocytes in the CA1 region of Alzheimer's disease hippocampi, associated with beta-amyloid-positive plaques.
Number of subjects: 0
Study 8915574 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of truncated trkB receptors found in senile plaques in Alzheimer's disease brains.
Number of subjects: 0
Study 8915574 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length trkB receptor expression in glial-like cells in the hippocampus of Alzheimer's disease brains.
Number of subjects: 0
Study 8915574 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated trk receptor mRNA levels in Alzheimer's disease brains as indicated by in-situ hybridisation studies.
Number of subjects: 0
Study 1910794 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 0.01 mg/kg
Number of subjects: 80
Study 7061727 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Charcoal (AC) 15 Gm
Number of subjects: 6
Study 7061727 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Charcoal + Sodium Sulfate (AC + SS) 15 Gm + 20 Gm
Number of subjects: 6
Study 7061727 — intervention group
Group type: COMPARATOR
Intervention: Control (Water alone)
Number of subjects: 6
Study 31237336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented Flaxseed Cake (FFSC)
Number of subjects: 420
Study 31237336 — intervention group
Group type: COMPARATOR
Intervention: Unfermented Flaxseed Cake (UFSC)
Number of subjects: 420
Study 31237336 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed Cake (FSC) supplementation
Number of subjects: 420
Study 28527420 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) followed by surgery with or without radiotherapy.
Number of subjects: 1553
Study 28527420 — intervention group
Group type: COMPARATOR
Intervention: Triple negative breast cancer
Number of subjects: 1553
Study 28527420 — intervention group
Group type: COMPARATOR
Intervention: HER2+ without trastuzumab
Number of subjects: 1553
Study 28527420 — intervention group
Group type: COMPARATOR
Intervention: HER2+ with trastuzumab
Number of subjects: 1553
Study 28527420 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥4 pathologically positive nodes and lack of pathological response
Number of subjects: 1553
Study 25204687 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Memory Decline (SMD) at follow-up
Number of subjects: 305
Study 25204687 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Memory Decline (SMD) at baseline
Number of subjects: 305
Study 25204687 — intervention group
Group type: COMPARATOR
Intervention: Controlling for anxiety and depression symptomatology
Number of subjects: 305
Study 23740422 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/day)
Number of subjects: 92
Study 23740422 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (35 mg/week)
Number of subjects: 92
Study 21519752 — intervention group
Group type: EXPERIMENTAL
Intervention: 5·10(8) cfu/day of L. plantarum CECT7315/7316 (low probiotic dose) (n = 13)
Number of subjects: 50
Study 21519752 — intervention group
Group type: EXPERIMENTAL
Intervention: 5·10(9) cfu/day of the probiotic mixture (high probiotic dose) (n = 19)
Number of subjects: 50
Study 21519752 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 50
Study 18356284 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantram repetition (spiritual practice of repeating a sacred word/phrase)
Number of subjects: 33
Study 18356284 — intervention group
Group type: COMPARATOR
Intervention: Delayed-treatment control
Number of subjects: 33
Study 16158402 — intervention group
Group type: EXPERIMENTAL
Intervention: Local influence measures for the Fine and Gray model for the subdistribution hazard
Number of subjects: 0
Study 16158402 — intervention group
Group type: EXPERIMENTAL
Intervention: Plot of local influence
Number of subjects: 0
Study 16158402 — intervention group
Group type: EXPERIMENTAL
Intervention: Real data set from a randomized clinical trial
Number of subjects: 0
Study 16158402 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study 12767365 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating therapy with mitomycin C (MMC) and bacillus Calmette‐Guerin (BCG)
Number of subjects: 304
Study 12767365 — intervention group
Group type: COMPARATOR
Intervention: BCG monotherapy
Number of subjects: 304
Study 12767365 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating therapy with MMC and BCG
Number of subjects: 304
Study 10711925 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular stapled procedure
Number of subjects: 40
Study 10711925 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan haemorrhoidectomy
Number of subjects: 40
Study 8261970 — intervention group
Group type: EXPERIMENTAL
Intervention: Subhepatic drains (group A, n = 50 patients)
Number of subjects: 100
Study 8261970 — intervention group
Group type: COMPARATOR
Intervention: No drains (group B, n = 50 patients)
Number of subjects: 100
Study 3910908 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilized streptokinase (streptodecase) administered to 37 patients
Number of subjects: 67
Study 3910908 — intervention group
Group type: COMPARATOR
Intervention: Native thrombolytic drugs (streptokinase or urokinase) administered to 30 patients
Number of subjects: 67
Study 31568306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative navigation system
Number of subjects: 50
Study 31568306 — intervention group
Group type: COMPARATOR
Intervention: No navigation system
Number of subjects: 50
Study 29973224 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (IVFe) administered intravenously 1000 mg (maximum dose 20 mg/kg) 3 days before and after surgery
Number of subjects: 214
Study 29973224 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 214
Study 29973224 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (IVFe)
Number of subjects: 214
Study 28272175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fluticasone 1,000 µg
Number of subjects: 147
Study 28272175 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 147
Study 26232949 — intervention group
Group type: EXPERIMENTAL
Intervention: Child‐pedestrians Anticipate and Act Hazard Perception Training (CA(2)HPT)
Number of subjects: 24
Study 26232949 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 23690356 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine hydrochloride-oxymetazoline hydrochloride nasal spray bilaterally with sham injection
Number of subjects: 45
Study 23690356 — intervention group
Group type: COMPARATOR
Intervention: Intra-oral lidocaine-epinephrine injection with buffered saline nasal spray bilaterally
Number of subjects: 45
Study 23690356 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 45
Study 20949350 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (6 mg/day) plus sildenafil (75 mg/day)
Number of subjects: 40
Study 20949350 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (6 mg/day) plus placebo
Number of subjects: 40
Study 18297438 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA granules (TK‐98) for 168 weeks
Number of subjects: 39
Study 18297438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 39
Study 16571382 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg daily risedronate for 3 years
Number of subjects: 7
Study 16571382 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg daily risedronate for 5 years
Number of subjects: 7
Study 16571382 — intervention group
Group type: COMPARATOR
Intervention: Comparison to healthy premenopausal women, n = 12
Number of subjects: 7
Study 14649206 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine (80 mg twice a day, intravenous perfusion for three weeks)
Number of subjects: 45
Study 14649206 — intervention group
Group type: COMPARATOR
Intervention: Control group (Steroid, cyclophosphamide, losartan, and dipyridamole)
Number of subjects: 45
Study 11811508 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% potassium nitrate/0.2% sodium fluoride mouthwash
Number of subjects: 50
Study 11811508 — intervention group
Group type: COMPARATOR
Intervention: 0.2% sodium fluoride control mouthwash
Number of subjects: 50
Study 9839635 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary surgery
Number of subjects: 0
Study 9839635 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 0
Study 8038977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine pretreatment
Number of subjects: 6
Study 8038977 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol mixed with lidocaine (40 mg)
Number of subjects: 6
Study 8038977 — intervention group
Group type: COMPARATOR
Intervention: Propofol at 4 degrees C
Number of subjects: 6
Study 8038977 — intervention group
Group type: COMPARATOR
Intervention: Saline pretreatment
Number of subjects: 6
Study 3193409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin plus doxycycline
Number of subjects: 126
Study 3193409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime plus doxycycline
Number of subjects: 126
Study 3193409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime alone
Number of subjects: 126
Study 3193409 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral combination therapy (cefoxitin plus doxycycline or ceftizoxime plus doxycycline)
Number of subjects: 126
Study 3193409 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (ceftizoxime alone)
Number of subjects: 126
Study 31505051 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention with self-management education
Number of subjects: 189
Study 31505051 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189
Study 27320133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-notification leaflet (intervention group)
Number of subjects: 4314
Study 27320133 — intervention group
Group type: COMPARATOR
Intervention: Trial recruitment pack (control group)
Number of subjects: 4314
Study 26290088 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Poly liner
Number of subjects: 61
Study 26290088 — intervention group
Group type: COMPARATOR
Intervention: ArComXL liner (Control)
Number of subjects: 61
Study 23406826 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC) added to pegylated interferon-α2b plus ribavirin (PR)
Number of subjects: 595
Study 23406826 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Number of subjects: 595
Study 23406826 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ribavirin
Number of subjects: 595
Study 22321499 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleb morphology with microcysts
Number of subjects: 176
Study 22321499 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleb morphology with non-vascular
Number of subjects: 176
Study 22321499 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase by 10 years
Number of subjects: 176
Study 19850549 — intervention group
Group type: EXPERIMENTAL
Intervention: Health e-cards delivering depression information
Number of subjects: 348
Study 19850549 — intervention group
Group type: COMPARATOR
Intervention: All conditions (including control)
Number of subjects: 348
Study 16847734 — intervention group
Group type: EXPERIMENTAL
Intervention: HYBRID (problem-based learning oriented structured modules)
Number of subjects: 0
Study 16847734 — intervention group
Group type: COMPARATOR
Intervention: TRAD (conventional teacher-centred course)
Number of subjects: 0
Study 16847734 — intervention group
Group type: EXPERIMENTAL
Intervention: HYBRID
Number of subjects: 0
Study 16847734 — intervention group
Group type: COMPARATOR
Intervention: TRAD
Number of subjects: 0
Study 15014183 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS 2.5 mg
Number of subjects: 126
Study 15014183 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (all doses)
Number of subjects: 126
Study 15014183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 11549929 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational training
Number of subjects: 182
Study 11549929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychoeducational training)
Number of subjects: 182
Study 9043563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1: Placement of a brightly colored label in the medication drawer and on the cover of the nursing medication card flip-chart.
Number of subjects: 0
Study 9043563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2: Placement of labels plus a five-minute structured patient-counseling session.
Number of subjects: 0
Study 9043563 — intervention group
Group type: COMPARATOR
Intervention: Control phase: Existing pharmacy system with no patient-specific information on DNIs.
Number of subjects: 0
Study 9043563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (label system and combined label-counseling system).
Number of subjects: 0
Study 8172701 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed evaluation method for treatment of otitis media
Number of subjects: 0
Study 8172701 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical test of significance
Number of subjects: 0